Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MediciNova (MNOV) Expected to Announce Quarterly Earnings on Wednesday
MediciNova (NASDAQ:MNOV) will be releasing earnings after the market closes on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-medicinova-inc-stock...
MarketBeat
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV)
D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of MediciNova in a report on Monday...
MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest
MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totaling 168,023 shares, a decline of 16.4% from the March...
MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm...
MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why
MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average - Should You Sell...
MarketBeat
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average - Here's What Happened
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average - Should You Sell...
MarketBeat
Maxim Group Reiterates "Buy" Rating for MediciNova (NASDAQ:MNOV)
Maxim Group reaffirmed a "buy" rating and set a $6.00 price objective on shares of MediciNova in a report on Monday...
MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have i...
MarketBeat

Advertisement|Remove ads.